The authors suggested that as more patients with MM receive monotargeted TCEs, an increasing number of patients may develop irreversible antigen loss and treatment with dual-antigen-targeting therapies, such as ISB 2001, could prevent such escape by killing cells expressing only BCMA or CD38, even if at a lower potency. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.